Welcome to PDS Biotechnology Corporation
Simple, safe and innovative immunotherapies targeting infectious diseases and cancer
PDS Biotechnology Corporation is a biopharmaceutical company applying the company’s platform Versamune™ nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the treatment of
cancer and infectious diseases.
Unlike typical vaccines which are only preventative, the patented Versamune™ nanoparticle leads to potent curative and preventative immune responses. The nanoparticles facilitate the uptake of disease-associated proteins and peptides by the cells of the immune system and simultaneously activate the immune system to generate a strong and specific immune response against the specific infected cells in the body, resulting in eradication of the cancer or viral disease. Superior prevention and cure of cancer has been demonstrated in head-to-head studies with the leading technologies. In preclinical studies, the company’s two lead VersamuneTM-based products to treat cancers caused by infection with the HPV virus and melanoma have both demonstrated superior efficacy in causing tumor eradication. NIH sponsored GLP toxicology studies have also demonstrated a very safe drug profile even at very high doses far exceeding the therapeutic dose.
Immunotherapies have been shown to provide significant potential in treating some of the most debilitating cancers and infectious diseases. However, the current technologies suffer from several drawbacks including high complexity and cost, as well as low potency and safety. The Versamune™ technology provides the solution.
The first Versamune™-based product, to treat HPV-related cancer and pre-cancerous lesions will enter human clinical trials in 2010.
The company's mission is to utilize its proprietary technology to pioneer the development of safe, simple and cost effective immunotherapies to cure and to prevent specific cancers and infectious diseases for which no cures exist.
